title: Transfusion-related acute lung injury and leucocyte-reacting antibodies.
abstract: OBJECTIVE
  Transfusion-related acute lung injury (TRALI) is underdiagnosed and underreported. This is why we present cases suspected for TRALI, in which leucocyte antibodies were examined.
  
  
  METHODS
  We analysed 44 patients with respiratory insufficiency, related to transfusion, who met criteria of acute lung injury (ALI). Lymphocyte and granulocyte antibodies were examined in donors and patients by six methods.
  
  
  RESULTS
  Based on recent trends, we divided patients into two groups: TRALI (without risk factors for ALI) and possible TRALI (with probable risk factors). The incidence of antibodies was 68.2%, the majority were human leucocyte antigen (HLA) class I and/or II, the minority were non-specific granulocyte antibodies; half of all detected antibodies, however, reacted with granulocytes. Antibodies were found in 17 donors (more often in TRALI than in possible TRALI) and in 19 patients (in four - suspected to be of the donor origin, which would diminish the number of antibodies to 15). In seven available cases, we observed cognate antigen and/or positive cross-match. In the majority of patients, TRALI occurred after transfusion of red cells, in 56.2%- stored above 14 days; all the units were non-leucoreduced. Lookback in two donors showed that transfusions in 20 patients did not result in reported TRALI, even in the patient with cognate antigen.
  
  
  CONCLUSIONS
  Our clinical observations suggest that to distinguish between TRALI and possible TRALI is difficult and the results are equivocal - it is worth considering whether it can be omitted. We have confirmed that antibodies are involved in TRALI, although their role is very complex. The role of stored red blood cells in the development of TRALI requires further observations in comparison with a control group of patients without TRALI.
authors.affiliation: Institute of Haematology and Blood Transfusion, Warsaw, Poland. zupanska@ihit.waw.pl
authors.forename: B
authors.initials: B
authors.lastname: Zupanska
authors.forename: M
authors.initials: M
authors.lastname: Uhrynowska
authors.forename: H
authors.initials: H
authors.lastname: Michur
authors.forename: K
authors.initials: K
authors.lastname: Maslanka
authors.forename: M
authors.initials: M
authors.lastname: Zajko
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D001782:Blood Donors; D001793:Blood Preservation / Q000009:adverse effects; D002648:Child; D017707:Erythrocyte Transfusion / Q000009:adverse effects; D005260:Female; D006098:Granulocytes / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000097:blood / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000097:blood / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012128:Respiratory Distress Syndrome / Q000097:blood / Q000209:etiology* / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II